Sanofi投资2500万美元给Adagene, 以推进结肠癌免疫疗法研究。 Sanofi invests $25M in Adagene to advance colorectal cancer immunotherapy research.

Adagene是一家生物技术公司,从Sanofi获得2 500万美元投资,用于推进癌症免疫疗法研究,特别是用于在结肠癌试验中进行称为muzastotug的治疗。 Adagene, a biotech firm, received a $25 million investment from Sanofi to advance cancer immunotherapy research, particularly for a treatment called muzastotug in colorectal cancer trials. 这项投资将有助于资助Adagene到2027年的业务,并扩大其在新药物开发方面的合作。 The investment will help fund Adagene's operations through 2027 and expand their collaboration on new drug development. Adagene公司在市场前贸易中的份额上升9.74%至2.14美元。 Shares of Adagene rose 9.74% to $2.14 in pre-market trading.